Munich/Essen, Jan. 13, 2026 – 2NA FISH GmbH, a Munich-based biotech developing a next-generation spatial RNA detection platform for oncology decision support, has secured additional pre-seed funding led by GF BRYCK Ventures, with follow-on investment from existing investor Twip. The capital will be used to further develop and validate 2NA FISH’s spatial RNA biomarker detection platform for research and translational use, expand early-access collaborations, and strengthen the software stack that enables robust analysis in routine pathology workflows.
2NA FISH’s platform combines nanostructure-enhanced probes with routine pathology workflows to deliver bright, specific signals and practical multiplexing on standard fluorescence microscopes – aiming to make spatial RNA biomarker testing more affordable and deployable in everyday lab and pathology settings. A proprietary, AI-based analysis application supports quantification and cell-level readouts to turn spatial RNA data into actionable biomarker information.
“This additional funding helps us translate strong lab results into real-world relevance – completing key validation milestones, broadening early-access collaborations, and hardening the software stack that research and pathology teams need,” says Christina Port, Founder and CEO of 2NA FISH. “We’re excited to work with GF BRYCK Ventures and to deepen our partnership with Twip as we prepare for the next phase.”
“2NA FISH targets clinically relevant multiplexing while keeping workflows pragmatic; a combination that can drive adoption in both research and applied settings” says Jan zur Hausen, Venture Partner at GF BRYCK Ventures. Fabian Hogrebe, Investment Manager at GF BRYCK Ventures, adds: “The early data are strong and the path to product is clear, with a thoughtful rollout to research and pathology partners.”
“We’re strengthening our commitment to 2NA FISH because of the team’s rapid product progress and first customer traction,” says Michael Adersberger, Managing Director and Investment Manager at Twip. “What convinced us most is the rare mix of scientific depth, execution power, and a clear vision to bring this innovation into real-world use.”
About 2NA FISH
2NA FISH GmbH is developing a nanostructure-enhanced spatial RNA detection platform that enables bright, specific, and multiplexed RNA biomarker analysis on standard fluorescence microscopes. Designed for routine pathology workflows, the platform enables translational oncology research and biomarker programs that benefit from spatial, cell-level RNA readouts. 2NA FISH is headquartered in Munich, Germany.
Learn more: https://2nafish.bio/
About GF BRYCK Ventures
GF BRYCK Ventures is a private venture capital investor in a wide range of innovative technologies across various industries. The fund supports forward-looking startups throughout Europe. The experienced fund management team, led by Ann-Christin Kortenbrede and Jan Gräfe, provides both capital and entrepreneurial expertise as well as industry access to support young startups on their path to commercial success. GF BRYCK Ventures works closely with BRYCK, the startup and innovation center initiated by the RAG-Stiftung and based in the Ruhr region.
Learn more: https://gruenderfonds-ruhr.com/
About Twip
Twip supports early-stage technology companies with the ambition to make a positive real-world impact, backing teams that combine strong technology with fast execution and a viable, scalable, and growing market.
Learn more: https://twip.de/